Headquartered in Hyderabad, Cohance Lifesciences is a global, innovation-driven CDMO platform specialising in high-value, end-to-end solutions across the full spectrum of a molecule’s lifecycle - from early-stage development to large-scale commercialisation - with a marquee Customer Base across Pharmaceuticals and Specialty Chemicals. 

With a focus on agility, innovation and global scalability, Cohance Lifesciences is reshaping the landscape of pharmaceutical manufacturing and development. The company collaborates with its customers to enhance their molecules and products, enabling them to deliver innovative solutions to their patients and consumers. 

Business area of the company

The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.

Business verticals of the company

• Pharma CDMO
• Specialty Chemicals
• API+

Achievements

Achieved B-rating 2024 disclosure both in Climate Change & Water Security.

Social Accountability SA8000.

Silver in Ecovadis Sustainability Assessment.

Pharmaceutical Supply Chain Initiative (PSCI) Supplier Partner- 2025.

British Safety Council’s International Safety Awards (ISA) 2025.

All facilities are certified with ISO 14001, ISO 45001.

Milestones

• 2020: The foundation was laid with the inclusion of RA Chem Pharma, known for its strong footprint in APIs, intermediates, and finished dosage formulations, setting the tone for a platform focused on quality and scientific depth.
• 2021: With the addition of ZCL Chemicals, the platform expanded its capability in complex intermediates, enhancing its ability to serve global pharmaceutical innovators.
• 2022: The journey progressed with Avra, bringing expertise in high-complexity chemistry and ADC payloads – positioning the platform to support next-generation therapeutics.
• 2023: Suven Pharmaceuticals merges with Cohance - Suven Pharmaceuticals, with its rich heritage in CRAMS and custom synthesis, joined hands with the growing platform. This marked a pivotal point where the vision of Cohance – a differentiated, technology-led CDMO platform – began to take shape.
• 2024: Expanding into next-gen therapeutic platforms - While the Cohance–Suven integration was underway, the platform advanced further with Sapala Organics (bringing oligonucleotide capabilities) and NJ Bio (offering end-to-end integrated ADC services), broadening scientific reach in novel modalities.
• 2025: Cohance Lifesciences announced a strategic investment of $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio.